A changing market: Genomic Vision's IP strategy
Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out.
New frontiers: potential barriers to patenting induced totipotent stem cell technology
Ethical considerations plus the ambiguity of the Biotech Directive are factors influencing the patentability of totipotent stem cells, says Andrew Sanderson.
Adapt or die: how to survive the patent cliff
Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators.
New horizons: biotech guidelines in Brazil
New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain.
Patents for self-replicating products: not so exhausting after all
When the US Supreme Court decided in favour of Monsanto in its case against a soybean farmer, it clarified the patent status of certain self-replicating technologies. In Europe, the result would probably have been the same, say Steven Zeman and Heike Vogelsang-Wenke.
Protecting plant products in Europe
Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe.
Room for improvement: enforcing data exclusivity provisions in Mexico
In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains.
Enough is enough: sufficiency and technical contribution
In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright.
Salad days: tomatoes, broccoli and radish patents
When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look.
'Because he fears': should generics fear the high court's quia timet injunctions?
For generic drug makers, previous bad behaviour may affect new litigation, especially when it comes to injunctions, as Bethan Hopewell and Geraldine Quinn explain.
